Therapeutic Response

PD-L1 >= 1% status confers therapeutic sensitivity to Durvalumab in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Imfinzi (durvalumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized durvalumab as a monotherapy for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose tumors express PD-L1 on >= 1% of tumor cells and whose disease has not progressed following platinum-based chemoradiation therapy.